Aldagen, the Durham biotechnology company that has had its IPO delayed repeatedly, has hired a new CEO.
The company announced today that Lyle A. Hohnke, a member of Aldagen's board since 2008, will succeed Tom Amick as CEO.
Hohnke was most recently a partner at Tullis Dickerson, a venture capital firm focused on health care. He also served as chairman and CEO of Diamond Animal Health.
"We appreciate the guidance Tom has given Aldagen over the years, and thank him for his many contributions that have brought the company to its current stage of development," said Richard Kent, chairman of Aldagen, in a release.
"Lyle's involvement with the company as a board member, and his significant fundraising and operational experience make him a great addition to Aldagen's executive management team."